Patentable Subject Matter: Pharmascience v Janssen
When are dosing regimens patentable? When does a claimed invention cross the line into an unpatentable method of medical treatment? This panel will examine the Supreme Court of Canada’s landmark decision in Pharmascience v. Janssen, in which the Court confirmed that methods of medical treatment remain unpatentable while upholding the validity of the dosing regimen claims at issue. Hear from experienced counsel on all sides of the issues as they discuss the Court’s reasoning, the principles established for assessing patentable subject matter, and the decision’s implications for pharmaceutical patent litigation and patentable subject matter more broadly.
Amy Grenon Tyr LLP (Toronto)
Bryan Norrie Aitken Klee LLP (Ottawa)
Kristin Wall Norton Rose Fulbright Canada LLP (Toronto)
Moderator: Zarya Cynader Gilbert’s LLP (Toronto)
Recent Comments